ストックスクリーナーアプリを入手
19.83
1.05%
-0.21
アフターアワーズ：
19.83
前日終値:
$20.04
開ける：
$19.9
24時間の取引高:
2.69M
Relative Volume:
2.92
時価総額：
$1.40B
収益：
$80.89M
当期純損益:
$-144.73M
株価収益率:
-6.6768
EPS:
-2.97
ネットキャッシュフロー:
$-83.87M
1週間 パフォーマンス:
-2.17%
1か月 パフォーマンス:
-12.41%
6か月 パフォーマンス:
-5.44%
1年 パフォーマンス:
+101.73%
1日の値動き範囲:
$19.66
$20.61
1週間の範囲:
$19.38
$21.67
52週間の値動き範囲:
$7.65
$29.56
Nurix Therapeutics Inc Stock (NRIX) Company Profile
名前
Nurix Therapeutics Inc
セクター
電話
(415) 660-5320
住所
1700 OWENS STREET, SUITE 205, SAN FRANCISCO
NRIX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
NRIX
Nurix Therapeutics Inc
|
19.83 | 1.40B | 80.89M | -144.73M | -83.87M | -2.66 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Nurix Therapeutics Inc Stock (NRIX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-12-10 | 開始されました | BTIG Research | Buy |
| 2024-12-06 | 開始されました | BMO Capital Markets | Outperform |
| 2024-10-24 | 開始されました | UBS | Buy |
| 2024-10-11 | 開始されました | Jefferies | Buy |
| 2024-09-06 | 再開されました | Robert W. Baird | Outperform |
| 2024-07-31 | 開始されました | Truist | Buy |
| 2023-06-26 | 再開されました | Oppenheimer | Outperform |
| 2023-03-09 | 開始されました | Barclays | Overweight |
| 2023-02-28 | 開始されました | Oppenheimer | Outperform |
| 2022-10-11 | 開始されました | Morgan Stanley | Equal-Weight |
| 2022-05-31 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2022-02-10 | 開始されました | Wells Fargo | Equal Weight |
| 2021-12-29 | 開始されました | H.C. Wainwright | Buy |
| 2021-10-14 | 開始されました | SVB Leerink | Outperform |
| 2021-06-04 | 再開されました | Robert W. Baird | Outperform |
| 2021-04-30 | 再開されました | Piper Sandler | Overweight |
| 2021-04-30 | 開始されました | RBC Capital Mkts | Outperform |
| 2021-04-14 | 開始されました | Berenberg | Buy |
| 2020-11-19 | 開始されました | Robert W. Baird | Outperform |
| 2020-08-18 | 開始されました | JP Morgan | Overweight |
| 2020-08-18 | 開始されました | Needham | Buy |
| 2020-08-18 | 開始されました | Piper Sandler | Overweight |
| 2020-08-18 | 開始されました | Stifel | Buy |
すべてを表示
Nurix Therapeutics Inc (NRIX) 最新ニュース
Jane Street Group LLC Has $3.54 Million Stake in Nurix Therapeutics, Inc. (NASDAQ:NRIX) - MarketBeat
State Street Corp Sells 337,262 Shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX) - Defense World
Nurix Therapeutics Receives U.S. FDA Fast Track Designation for NX-5948 for the Treatment of Relapsed or Refractory Waldenstrom's Macroglobulinemia - The Manila Times
Nurix Therapeutics Receives U.S. FDA Fast Track Designation - GlobeNewswire
Nurix's BTK Degrader NX-5948 Earns FDA Fast Track Status for Rare Blood Cancer Treatment - StockTitan
State Street Corp Cuts Stock Holdings in Nurix Therapeutics, Inc. (NASDAQ:NRIX) - MarketBeat
Nurix Therapeutics' SWOT analysis: btk degrader stock shows promise amid challenges - Investing.com
Lord Abbett & CO. LLC Purchases Shares of 350,640 Nurix Therapeutics, Inc. (NASDAQ:NRIX) - MarketBeat
Brokerages Set Nurix Therapeutics, Inc. (NASDAQ:NRIX) Target Price at $30.35 - MarketBeat
When (NRIX) Moves Investors should Listen - Stock Traders Daily
Nurix Therapeutics, Inc. (NASDAQ:NRIX) Stake Boosted by The Manufacturers Life Insurance Company - Defense World
BTIG Initiates Coverage of Nurix Therapeutics (NRIX) with Buy Recommendation - MSN
Nurix Therapeutics, Inc. (NASDAQ:NRIX) Shares Acquired by Fmr LLC - MarketBeat
Is Nurix Therapeutics (NRIX) the Worst ARK Stock to Buy According to Short Sellers? - MSN
Nurix Therapeutics (NASDAQ:NRIX) Given New $35.00 Price Target at HC Wainwright - MarketBeat
Nurix Therapeutics, Inc. (NASDAQ:NRIX) Shares Purchased by Wellington Management Group LLP - MarketBeat
Nurix Therapeutics (NASDAQ:NRIX) Coverage Initiated at BTIG Research - MarketBeat
Nurix Therapeutics' (NRIX) Buy Rating Reiterated at Needham & Company LLC - MarketBeat
Nurix Therapeutics Reports Promising Trial Results for NX-5948 - TipRanks
Nurix Therapeutics's SWOT analysis: btk degrader stock shows promise amid challenges By Investing.com - Investing.com South Africa
Nurix Therapeutics's SWOT analysis: btk degrader stock shows promise amid challenges - Investing.com India
Nurix Therapeutics Presents New Positive Data from Phase 1a/1b Clinical Trial of NX-5948 in Chronic Lymphocytic Leukemia at the 66th American Society of Hematology Annual Meeting - The Manila Times
Nurix Therapeutics Presents New Positive Data from Phase - GlobeNewswire
Charles Schwab Investment Management Inc. Sells 111,684 Shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX) - MarketBeat
Nurix Therapeutics (NASDAQ:NRIX) Shares Up 8.3%Here's What Happened - MarketBeat
Nurix Therapeutics (NASDAQ:NRIX) Now Covered by BMO Capital Markets - MarketBeat
Polar Asset Management Partners Inc. Purchases Shares of 27,000 Nurix Therapeutics, Inc. (NASDAQ:NRIX) - MarketBeat
Decoding 9 Analyst Evaluations For Nurix Therapeutics - Inkl
Where are the Opportunities in (NRIX) - Stock Traders Daily
Nurix Therapeutics, Inc. (NASDAQ:NRIX) Shares Sold by Redmile Group LLC - MarketBeat
Why Is Nurix Therapeutics, Inc. (NRIX) Among the Best Small-Cap Biotech Stocks With Massive Potential According to Hedge Funds? - Insider Monkey
10 Best Small-Cap Biotech Stocks with Massive Potential According to Hedge Funds - Insider Monkey
Patient Square Capital LP Makes New Investment in Nurix Therapeutics, Inc. (NASDAQ:NRIX) - MarketBeat
Parkman Healthcare Partners LLC Decreases Holdings in Nurix Therapeutics, Inc. (NASDAQ:NRIX) - MarketBeat
Cinctive Capital Management LP Buys Shares of 105,228 Nurix Therapeutics, Inc. (NASDAQ:NRIX) - MarketBeat
Nurix Therapeutics chief legal officer sells $125,155 in stock By Investing.com - Investing.com Canada
Nurix Therapeutics chief legal officer sells $125,155 in stock - Investing.com
Nurix Therapeutics Announces Webcast To Review New Data - GlobeNewswire
Nurix Therapeutics Announces Webcast to Review New Data from Its Phase 1 Clinical Trial of BTK Degrader NX-5948 Presented At the American Society of Hematology Annual Meeting - Marketscreener.com
Nurix Therapeutics Announces Webcast To Review New Data from Its Phase 1 Clinical Trial of BTK Degrader NX-5948 Presented at the 66th American Society of Hematology (ASH) Annual Meeting - The Manila Times
Fred Alger Management LLC Increases Stock Position in Nurix Therapeutics, Inc. (NASDAQ:NRIX) - MarketBeat
Wasatch Advisors LP Has $15.92 Million Holdings in Nurix Therapeutics, Inc. (NASDAQ:NRIX) - MarketBeat
23,578 Shares in Nurix Therapeutics, Inc. (NASDAQ:NRIX) Purchased by Dynamic Technology Lab Private Ltd - MarketBeat
Vestal Point Capital LP Sells 75,000 Shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX) - MarketBeat
Massachusetts Financial Services Co. MA Sells 28,756 Shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX) - MarketBeat
Nurix Therapeutics CEO to Present at Piper Sandler Healthcare Conference | NRIX Stock News - StockTitan
Nurix Therapeutics to Participate in the Piper Sandler 36th Annual Healthcare Conference - GlobeNewswire
(NRIX) Proactive Strategies - Stock Traders Daily
GSA Capital Partners LLP Sells 15,134 Shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX) - Defense World
Nurix Therapeutics, Inc. (NASDAQ:NRIX) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
Nurix Therapeutics, Inc. (NASDAQ:NRIX) Receives Average Rating of “Moderate Buy” from Analysts - Defense World
Nurix Therapeutics Inc (NRIX) 財務データ
収益
当期純利益
現金流量
EPS
Nurix Therapeutics Inc (NRIX) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Ring Christine | Chief Legal Officer |
Dec 02 '24 |
Sale |
21.73 |
5,760 |
125,155 |
28,084 |
2.88%
2.65%
大文字化:
|
ボリューム (24 時間):